IP Library Granted Patent US 8,575,395
Granted Patent B2
US 8,575,395 · App. 13/226,061 · Granted Nov 5, 2013

Method for the preparation of cinacalcet and intermediates and impurities thereof

Inventors: Vijayavitthal Thippannachar Mathad (Maharashtra, IN); Navnath Chintaman Niphade (Maharashtra, IN); Gorakshanath Balasaheb Shinde (Maharashtra, IN); Sharad Subhash Ippar (Maharashtra, IN); Shrikant Prataprao Deshmukh (Maharashta, IN); Raghavendra Kumar Panchangam (Maharashtra, IN)
Assignees: Amneal Pharmaceuticals, LLC; Megafine Pharma (P) Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,575,395
App. No.
13/226,061
Granted
Nov 5, 2013
Kind
B2
Abstract

A method for the preparation of Cinacalcet is disclosed comprising treating (R)-1-naphthyl ethylamine with an aromatic aldehyde to form (1R)-1-(2-naphthyl)-N-(aryl methylene)ethanamine derivative of Formula (IV), which is further treated with 1-(3-halopropyl)-3-(trifluoromethyl)benzene of Formula (V) to obtain an iminium salt of Formula (VI), followed by hydrolysis to obtain Cinacalcet free base.

Claims (59)

1. A method for the preparation of a compound of Formula (I) or salts thereof,

the method comprising:

a. reacting a compound of the Formula (II) and a compound of Formula (III) to form a compound of Formula (IV);

wherein

Ar is benzyl-, phenyl- or naphthyl-, which may be mono- or di- or poly substituted with alkyl, aryl, alkoxy, amino, hydroxyl, halogen, and nitro groups;

b. treating the compound of Formula (IV) obtained from step (a) with a compound of Formula (V) to form a compound of Formula (VI);

wherein;

Ar is as described above,

X is chloro, bromo or iodo; and

c. treating the compound of Formula (VI) with water and/or acid solution to obtain a compound of Formula (I) or salts thereof;

2. The method according to claim 1 , wherein the step (a) is carried out at a temperature from about 10° C. to 150° C.

3. The method according to claim 2 wherein the step (a) is carried out in the presence of a solvent.

4. The method according to claim 3 , wherein the solvent is selected from the group consisting of hydrocarbons, alcohols, C 1 -C 10 ether, C 5 -C 8 cyclic ether, C 2 -C 10 aliphatic ester, C 2 -C 8 aliphatic amides, sulfoxide, C 1 -C 8 chlorinated hydrocarbon, 1-ethyl-3-methyl imidazolium ethylsulfate, and mixtures thereof.

5. The method according to claim 1 wherein, the compound of Formula (III) is selected from benzaldehyde, salisaldehyde, p-hydroxylbenzaldehyde, o-chlorobenzaldehyde, p-methoxy benzaldehyde, o-methoxy benzaldehyde, and p-nitrobenzaldehyde.

6. The method according to claim 1 , further comprising isolating the compound of Formula (I) or a salt thereof in a crystalline form.

7. The method according to claim 1 , wherein the step (b) is carried out at a temperature of 80° C. to 180° C.

8. The method as according to claim 7 , wherein the step (b) is carried out in the presence of a solvent.

9. The method according to claim 8 , wherein the solvent is selected from the group consisting of hydrocarbons, alcohols, C 1 -C 10 ethers, C 5 -C 8 cyclic ethers, C 2 -C 10 aliphatic esters, C 2 -C 8 aliphatic amides, sulfoxides, C 1 -C 8 chlorinated hydrocarbons, 1-ethyl-3-methyl imidazolium ethyl sulfate, and mixtures thereof.

10. The method according to claim 1 , wherein the step (c) is carried out at a temperature of about 20° C. to 60° C.

11. The method according to claim 10 , wherein the step (c) is carried out in the presence of a solvent.

12. The method according to claim 11 , wherein the solvent is selected from the group consisting of hydrocarbons, alcohols, C 1 -C 10 ethers, C 5 -C 8 cyclic ethers, C 2 -C 10 aliphatic esters, C 2 -C 8 aliphatic amides, sulfoxides, C 1 -C 8 chlorinated hydrocarbons, 1-ethyl-3-methyl imidazolium ethyl sulfate, and mixtures thereof.

13. The method according to claim 1 , further comprising isolation of the compound of Formula (I) or salts thereof by:

I. cooling the reaction mass of step (c) and diluting it with water and a water-immiscible organic solvent;

II. adjusting the pH of the reaction mixture of Step I to a pH of about 10;

III. separating the organic layer comprising the compounds of Formula (I) or salts thereof, Formula (II) and Formula (III), from the aqueous layer comprising the compound of Formula (V);

IV. washing the organic layer separated in Step III with water;

V. further washing the organic layer of Step IV with a solution of sodium meta-bisulphite to remove the compound of Formula (III);

VI. diluting the organic layer of Step V with water and adjusting the pH to about 1 to about 5;

VII. separating the organic layer of Step VI comprising the compound of Formula (I) or salts thereof from the aqueous layer comprising the compound of Formula (II);

VIII. washing the organic layer obtained from Step VII with water and adjusting the pH of the organic layer to about 8 to about 10; and

IX. separating the organic layer mostly comprising the compound of Formula (I) or a salt thereof, and recovering the compound of Formula (I) or salt thereof by removing the solvent from the organic layer.

14. The method according to claim 13 , wherein the water-immiscible organic solvent is selected from the group consisting of hydrocarbons, esters, ethers, chlorinated hydrocarbons and mixtures thereof.

15. The method according to claim 1 , further comprising isolation of a hydrochloride salt of the compound of Formula (I) by

I. cooling the reaction mass of step (c) and diluting it with water and a water-immiscible organic solvent;

II. adjusting the pH of the reaction mixture of step I to a pH of around 10;

III. separating the organic layer comprising the compounds of Formula (I) or salts thereof, Formula (II) and Formula (III), from the aqueous layer comprising the compound of Formula (V);

IV. washing the organic layer separated in step III with water;

V. further washing the organic layer of step IV with a solution of sodium metabisulfite to remove the compound of Formula (III);

VI. diluting the organic layer of step V with water and adjusting the pH to about 1 to about 5 by adding hydrochloric acid to obtain a hydrochloride salt of the compound of Formula (I);

VII. separating the organic layer of step VI and further washing it with water; and

VIII. removing the solvent from the organic layer to obtain a hydrochloride salt of the compound of Formula (I).

16. The method according to claim 15 , wherein the water-immiscible solvent is selected from the group consisting of hydrocarbons, esters, ethers, chlorinated hydrocarbons, and mixtures thereof.

17. A compound of the Formula (VI),

wherein,

Ar is benzyl-, phenyl- or naphthyl-, which may be mono- or di- or poly substituted with alkyl, aryl, alkoxy, amino, hydroxyl, halogen, or nitro group; and

X is chloro, bromo or iodo.

18. A method of preparing the compound of claim 17 , comprising

a. reacting a compound of Formula (II) and a compound of Formula (III) to obtain a compound of Formula (IV);

wherein

Ar is benzyl-, phenyl- or naphthyl-, which may be mono- or di- or poly substituted with alkyl, aryl, alkoxy, amino, hydroxyl, halogen, and nitro groups; and

b. treating the compound of Formula (IV) with a compound of Formula (V) to obtain a compound of Formula (VI),

wherein

Ar is as defined above, and

X is chloro, bromo, or iodo.

19. The method according to claim 18 , wherein the step (a) is carried out at a temperature of 10° C. to 150° C.

20. The method according to claim 19 , wherein the step (a) is carried out in the presence of a solvent.

21. The method according to claim 20 , wherein the solvent is selected from the group consisting of a hydrocarbons, alcohols, C 1 -C 10 ethers, C 5 -C 8 cyclic ethers, C 2 -C 10 aliphatic esters, C 2 -C 8 aliphatic amides, sulfoxides, C 1 -C 8 chlorinated hydrocarbons, 1-ethyl-3-methyl imidazolium ethylsulfate, and mixtures thereof.

22. The method according to claim 18 , wherein the compound of Formula (III) is selected from benzaldehyde, salisaldehyde, p-hydroxy benzaldehyde, o-chlorobenzaldehyde, p-methoxy benzaldehyde, o-methoxy benzaldehyde, and p-nitrobenzaldehyde.

23. A method of preparing a compound of Formula (I) or a salt thereof, comprising reacting the compound of claim 17 to produce the compound of Formula (I).

Assignments (14)
PATENT SECURITY AGREEMENT Recorded Aug 1, 2025
From: AMNEAL PHARMACEUTICALS LLC; IMPAX LABORATORIES, LLC; GEMINI LABORATORIES, LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 072312/0127 →
RELEASE OF SECURITY INTEREST IN PATENTS AT R/F 060050/0224 Recorded Jan 21, 2025
From: JPMORGAN CHASE BANK, N.A., AS AGENT
To: AMNEAL PHARMACEUTICALS LLC; IMPAX LABORATORIES, LLC
Reel/Frame 069958/0509 →
SECURITY INTEREST Recorded Nov 17, 2023
From: AMNEAL PHARMACEUTICALS LLC
To: JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT
Reel/Frame 065602/0692 →
PATENT SECURITY AGREEMENT Recorded Jun 10, 2022
From: AMNEAL PHARMACEUTICALS LLC; IMPAX LABORATORIES, LLC; GEMINI LABORATORIES LLC
To: TRUIST BANK. AS ADMINISTRATIVE AGENT
Reel/Frame 060329/0568 →
PATENT SECURITY AGREEMENT (TERM LOAN) Recorded May 12, 2022
From: AMNEAL PHARMACEUTICALS LLC; IMPAX LABORATORIES, LLC
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT
Reel/Frame 060050/0224 →
RELEASE OF SECURITY INTEREST IN PATENTS (037112/0271) Recorded May 4, 2018
From: HEALTHCARE FINANCIAL SOLUTIONS, LLC, ACTING IN ITS CAPACITY AS THE SUCCESSOR ADMINISTRATIVE AGENT TO GENERAL ELECTRIC CAPITAL CORPORATION
To: AMNEAL PHARMACEUTICALS LLC
Reel/Frame 046105/0097 →
RELEASE OF SECURITY INTEREST IN PATENTS (037112/0292) Recorded May 4, 2018
From: HEALTHCARE FINANCIAL SOLUTIONS, LLC, ACTING IN ITS CAPACITY AS THE SUCCESSOR ADMINISTRATIVE AGENT TO GENERAL ELECTRIC CAPITAL CORPORATION
To: AMNEAL PHARMACEUTICALS LLC
Reel/Frame 046105/0172 →
ASSIGNMENT OF INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Nov 16, 2015
From: GENERAL ELECTRIC CAPITAL CORPORATION, AS RETIRING AGENT
To: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS SUCCESSOR AGENT
Reel/Frame 037112/0292 →
ASSIGNMENT OF INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Nov 16, 2015
From: GENERAL ELECTRIC CAPITAL CORPORATION, AS RETIRING AGENT
To: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS SUCCESSOR AGENT
Reel/Frame 037112/0271 →
SECURITY AGREEMENT Recorded Nov 1, 2013
From: AMNEAL PHARMACEUTICALS LLC
To: GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
Reel/Frame 031536/0732 →
SECURITY AGREEMENT Recorded Nov 1, 2013
From: AMNEAL PHARMACEUTICALS LLC
To: GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
Reel/Frame 031534/0104 →
RELEASE OF SECURITY INTEREST Recorded Nov 1, 2013
From: GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
To: AMNEAL PHARMACEUTICALS LLC
Reel/Frame 031528/0413 →
SECURITY AGREEMENT Recorded Dec 8, 2012
From: AMNEAL PHARMACEUTICALS LLC
To: GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
Reel/Frame 029431/0177 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 30, 2012
From: MATHAD, VIJAYAVITTHAL THIPPANNACHAR; NIPHADE, NAVNATH CHINTAMAN; SHINDE, GORAKSHANATH BALASAHEB; IPPAR, SHARAD SUBHASH; DESHMUKH, SHRIKANT PRATAPRAO; PANCHANGAM, RAGHAVENDRA KUMAR
To: AMNEAL PHARMACEUTICALS, LLC; MEGAFINE PHARMA (P) LTD.
Reel/Frame 028127/0340 →
Priority Claims (1)
IN 516/MUM/2009 · Mar 9, 2009 · national
Continuity (2)
Continuation In Part PCTIN2009000557 · Oct 8, 2009
Related Publication 20110319663A1 · Dec 29, 2011